Parallel Arm Trial of AD109 and AD504 In Patients With OSA
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study
to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in
Obstructive Sleep Apnea.